Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 28, 2013

Conditions
MalariaPlasmodium Falciparum
Interventions
BIOLOGICAL

Plasmodium falciparum sporozoites 2sites

Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites

BIOLOGICAL

Plasmodium falciparum sporozoites 1 site

Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites

BIOLOGICAL

Plasmodium falciparum sporozoites 1site

Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites

Trial Locations (1)

OX3 7LJ

Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford

All Listed Sponsors
collaborator

Sanaria Inc.

INDUSTRY

lead

University of Oxford

OTHER

NCT01465048 - Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe | Biotech Hunter | Biotech Hunter